About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Breaking News
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis
Breaking News
TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active PsA at risk for structural damage in Phase 3b study
Breaking News
Pioneering trial could 'switch off' arthritis
Breaking News
Top Story Lilly's Omvoh scores second IBD win with FDA nod in Crohn's
Breaking News
J&J, Protagonist’s oral anti-IL-23 hits main goals in pivotal psoriasis studies
Breaking News
A disease-associated gene desert directs macrophage inflammation through ETS2. See our full slide deck review of this key paper!
Breaking News
Guselkumab Demonstrates Superiority Versus Placebo and Ustekinumab in Phase 3 Crohn’s Disease Program
Breaking News
Gastroenterology Launch is now LIVE! Key Historical Publications and Literature Highlights Available Now
Breaking News
Sarcoidosis Awareness Month
Breaking News
Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-blind, Placebo-controlled, Withdrawal, Efficacy, and Safety Trial
Publications
Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)
Podcasts
Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab
Podcasts
Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA
Podcasts
Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA
Publications
A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
Podcasts
Author Interview: Professor Filip Rob, 2025
Podcasts
Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2
Publications
Upadacitinib in psoriatic arthritis with prior TNF-inhibitor failure: a 56-week real-world study
Publications
A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK
Publications
Long‑term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: Treatment persistence is differentially affected by disease phenotype, obesity and sex
Podcasts
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
Podcasts
Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab
Publications
Long-term management of elderly patients with rheumatoid arthritis treated with tocilizumab: comparison of patients over and under 75 years old
Podcasts
Pathways Modulating IMIDs: Webinar Highlights Podcast
Publications
Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: A target trial emulation study
Publications
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
Publications
Clinical efficacy of JAK inhibitors for rheumatoid arthritis patients with poor-prognosis factors: The ANSWER cohort study
Publications
Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib
Publications
Association of BMI, BMR, BSA, and body weight with psoriasis severity and treatment response: Evidence from a real-world cohort
Publications
Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study
Publications
Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial
Publications